News

Pfizer's 7.45% dividend yield can't offset weak growth, declining EPS, and patent risks. Read more on PFE and why analysts ...
We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look ...
Zacks Investment Research on MSN1d
Should Value Investors Buy Pfizer (PFE) Stock?
While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With ...
Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...
Pfizer’s recent earnings look solid at first glance, but there’s a quirky twist. A US$7 billion unusual expense dragged down ...
Pfizer Inc. (PFE) is currently at $23.04, up $0.77 or 3.43% --On pace for largest percent increase since Dec. 17, 2024, when it rose 4.67% --Down 62.38% from its all-time closing high of $61.25 on Dec ...
But when a dividend yield reaches ultrahigh levels, investors can feel a heightened level of uncertainty. Wondering if Pfizer ...
That study, based on an older return calculation method that has since been widely replicated, highlighted the strong ...
Pfizer (NYSE:PFE) is one of the world’s largest pharmaceutical companies, but at $22.59 per share as of this writing, the ...
Pfizer has received a “Moderate Buy” consensus from fifteen analysts, signaling cautious optimism rather than fanfare. One ...